Another alternative mechanism that may be claimed to be in the background of the impact of HLA-II expression in immunotherapy efficiency is the possibility of the activation of helper and cytotoxic CD4+ T lymphocytes by tumor antigens presented by these molecules [31]. The gene discussed is CD4; the disease is neoplasm.